H. Hochster

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.

M. Green, A. Zeleniuch‐Jacquotte, J. Speyer, 1990, Cancer treatment reviews.

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

S. Wadler, H. Hochster, M. Green, 1992, Journal of the National Cancer Institute.